Cargando…

Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD

BACKGROUND: The adoption of clinical practice guideline recommendations for COPD is suboptimal. Determining the barriers to the implementation of these practice guidelines may help improve patient care. OBJECTIVE: To determine whether barriers to the use of pharmacotherapy according to practice guid...

Descripción completa

Detalles Bibliográficos
Autores principales: Price, Lea, Billups, Sarah J., Rice, Melissa A., Hartsfield, Cynthia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155154/
https://www.ncbi.nlm.nih.gov/pubmed/25214921
_version_ 1782333546276323328
author Price, Lea
Billups, Sarah J.
Rice, Melissa A.
Hartsfield, Cynthia
author_facet Price, Lea
Billups, Sarah J.
Rice, Melissa A.
Hartsfield, Cynthia
author_sort Price, Lea
collection PubMed
description BACKGROUND: The adoption of clinical practice guideline recommendations for COPD is suboptimal. Determining the barriers to the implementation of these practice guidelines may help improve patient care. OBJECTIVE: To determine whether barriers to the use of pharmacotherapy according to practice guidelines are related primarily to patient or prescriber factors. METHODS: Retrospective cohort study. Members of a health maintenance organization identified as having spirometry-defined COPD ranging from stage II to IV. Electronic medical records were reviewed for documentation of the following: 1) patient affordability issues, 2) history of an adverse drug reaction, 3) history of inefficacy to therapy, and 4) prescription history. RESULTS: A total of 111 medical records were reviewed. There were 51% of patients who had not filled medications that had been prescribed in accordance with guidelines and 43% did not have the guideline recommended medications prescribed in the previous year. Only 4% and 2% of patients had documented inefficacy and affordability issues, respectively. There were no reported cases of adverse drug reactions. CONCLUSIONS: This study provides insight to the acceptance of COPD treatment recommendations by patients and providers. Further research is needed to design interventions to reduce barriers and optimize COPD treatment.
format Online
Article
Text
id pubmed-4155154
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Centro de Investigaciones y Publicaciones Farmaceuticas
record_format MEDLINE/PubMed
spelling pubmed-41551542014-09-11 Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD Price, Lea Billups, Sarah J. Rice, Melissa A. Hartsfield, Cynthia Pharm Pract (Granada) Original Research BACKGROUND: The adoption of clinical practice guideline recommendations for COPD is suboptimal. Determining the barriers to the implementation of these practice guidelines may help improve patient care. OBJECTIVE: To determine whether barriers to the use of pharmacotherapy according to practice guidelines are related primarily to patient or prescriber factors. METHODS: Retrospective cohort study. Members of a health maintenance organization identified as having spirometry-defined COPD ranging from stage II to IV. Electronic medical records were reviewed for documentation of the following: 1) patient affordability issues, 2) history of an adverse drug reaction, 3) history of inefficacy to therapy, and 4) prescription history. RESULTS: A total of 111 medical records were reviewed. There were 51% of patients who had not filled medications that had been prescribed in accordance with guidelines and 43% did not have the guideline recommended medications prescribed in the previous year. Only 4% and 2% of patients had documented inefficacy and affordability issues, respectively. There were no reported cases of adverse drug reactions. CONCLUSIONS: This study provides insight to the acceptance of COPD treatment recommendations by patients and providers. Further research is needed to design interventions to reduce barriers and optimize COPD treatment. Centro de Investigaciones y Publicaciones Farmaceuticas 2007 2007-06-18 /pmc/articles/PMC4155154/ /pubmed/25214921 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Price, Lea
Billups, Sarah J.
Rice, Melissa A.
Hartsfield, Cynthia
Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD
title Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD
title_full Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD
title_fullStr Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD
title_full_unstemmed Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD
title_short Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD
title_sort investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of copd
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4155154/
https://www.ncbi.nlm.nih.gov/pubmed/25214921
work_keys_str_mv AT pricelea investigationofbarrierstoclinicalpracticeguidelinerecommendedpharmacotherapyinthetreatmentofcopd
AT billupssarahj investigationofbarrierstoclinicalpracticeguidelinerecommendedpharmacotherapyinthetreatmentofcopd
AT ricemelissaa investigationofbarrierstoclinicalpracticeguidelinerecommendedpharmacotherapyinthetreatmentofcopd
AT hartsfieldcynthia investigationofbarrierstoclinicalpracticeguidelinerecommendedpharmacotherapyinthetreatmentofcopd